InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,266.95
(
-0.74%
)
US TECH 100
18,178.00
(
-1.14%
)
Dow Jones
38,441.54
(
-1.06%
)
Brent Oil
83.27
(
-0.13%
)
Bitcoin
67,602.50
(
0.03%
)
Post# of 251971
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119725
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: o post# 208764

Tuesday, 02/07/2017 9:51:26 AM

Tuesday, February 07, 2017 9:51:26 AM

Post# of 251971
BMY/IPH.PA—Endpoints blog on failure of Lirilumab phase-2 in AML has some misleading comments:

https://endpts.com/bristol-myers-partner-innate-concedes-a-phii-flop-for-io-drug-lirilumab-in-fighting-aml

More than five years ago Bristol-Myers Squibb heralded a $465 million deal to partner with Innate Pharma on its natural killer cell cancer drug lirilumab.

Not exactly. The up-front amount BMY paid in the Lirilumab deal was only $35M (#msg-64935883).

This is the latest in a series of clinical setbacks for Bristol-Myers’ Opdivo, which has been pummeled by the swift advance of Merck’s Keytruda in front¬line lung cancer.

The failed phase-2 trial in AML did not even involve Opdivo—it tested Lililumab monotherapy vs placebo. BMY still plans to test Opdivo in combination with Lirilumab in several cancer types.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up